Aggressive non-
Conditions
Interventions
atorvastatin 40 mg/day
start concomitantly with chemotherapy,
continuously until end of chemotherapy and complete echocardiogram at the end of study or until unacceptable adverse event,placebo
start concomitantly with chemotherapy,
continuously until end of chemotherapy and complete echocardiogram at the end of study or until unacceptable adverse event
Active Comparator Drug,Placebo Comparator Drug
Sponsors
Faculty of Medicine Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients 18-70 years old, who recently diagnosed with lymphoma and assigned to receive CHOP and R-CHOP regimens 2. Normal sinus rhythm with baseline LVEF>50% 3. ECOG performance status 0-2
Exclusion criteria
Exclusion criteria: 1. Pre-existing heart failure, coronary artery disease, structural heart disease 2. Prior mediastinal radiotherapy and ongoing or expected need to be treated with mediastinal radiotherapy 3. Liver impairment, defined as AST or ALT >3 times of upper limit of normal, TB >2 times of upper limit of normal; not considering form involvement of lymphoma 4. Alcoholism, alcohol dependent 5. Ongoing or expected need to be treated with statin, ACEIs, ARBs or beta-blocker from other conditions Allergic to statin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pro BNP baseline, every cycle of chemotherapy blood exam | — |
Secondary
| Measure | Time frame |
|---|---|
| cardiac markers baseline, every cycle of chemotherapy blood exam,echocardiogram baseline and at the end of chemotherapy echocardiogram, global longitudinal strain,oxidative stress marker baseline, every cycle of chemotherapy blood exam | — |
Countries
Thailand
Contacts
Public ContactAtisa Koonarat
Faculty of Medicine Chiang Mai University
Outcome results
None listed